Cholestasis, defined as a hereditary or an acquired disruption of bile flow, is a liver disease caused by reduced bile acid (BA) efflux from hepatocytes (intrahepatic) or bile duct obstruction (extrahepatic), resulting in BA accumulation and serious liver injury ([@B1]). Because it has been broadly defined as any condition in which substances excreted into bile such as BA and phospholipids are retained, various etiologies are associated with cholestasis, which typically causes predominant elevations of serum BA and bilirubin levels at later stages ([@B2]). Intrahepatic cholestasis occurs, not only in certain liver diseases driven by external factors such as viral, alcoholic, and drug-induced hepatitis, but also in genetic defects, including progressive familial intrahepatic cholestasis (PFIC). PFIC is currently categorized as a heterogeneous group of five autosomal recessive disorders that usually present with intrahepatic cholestasis in infancy or childhood and cause portal hypertension, cirrhosis, and liver failure ([@B3]). Initially, three main types of PFIC were known caused by mutations in*ATP8B1* (PFIC1),*ABCB11* (PFIC2), and*ABCB4* (PFIC3) ([@B4]). Additional types of PFIC with*TJP5* and*NR1H4* mutations have recently been designated PFIC4 and PFIC5, respectively ([@B3]).

We previously reported severe neonatal cholestasis in human patients with loss of function mutations in*NR1H4* (PFIC5), encoding the farnesoid X receptor (FXR) gene ([@B3],[@B5]). FXR is a BA-activated nuclear receptor that regulates the BA metabolism, suppressing BA synthesis and stimulating enterohepatic BA circulation by inhibition of cytochrome P450 (CYP), family 7, subfamily a, polypeptide 1 (CYP7A1) and induction of the bile salt export pump (BSEP) ([@B6]). Loss of FXR function in humans causes severe cholestasis with low-to-normal serum*γ*-glutamyl transferase (GGT) activity, undetectable BSEP expression, and conjugated hyperbilirubinemia ([@B5]). In contrast to the severe cholestatic liver injury in human patients, ablation of the mouse*Nr1h4*/*Fxr* gene results in a mild increase of BA and does not cause hepatomegaly and liver failure at a young age, suggesting the presence of potential compensatory mechanisms ([@B5],[@B7]).

Previously, we found that combined disruption of two nuclear receptors,*Nr1h4*/*Fxr* and*Nr0b2*/*Shp*, results in severe juvenile-onset cholestasis in mice with an enlarged liver size and accelerated liver damage ([@B8]). Small heterodimer partner (SHP) is a transcriptional repressor and a direct FXR target gene. It interacts with a variety of other nuclear receptors such as hepatocyte nuclear receptor 4*α*, liver receptor homolog-1, and peroxisome proliferator--activated receptors (PPARs) and blocks their transactivation ([@B9]). Thus, SHP induction by FXR inhibits*Cyp7a1* expression by inhibiting liver receptor homolog-1--mediated and hepatocyte nuclear receptor 4*α*--mediated transactivation, resulting in suppression of*de novo* BA synthesis ([@B6],[@B12]). In contrast to*Fxr* or*Shp* single knockouts, complete deletion of*Fxr* and*Shp* \[double knockout (DKO)\] leads to severe liver damage due to uncontrolled BA overload. Similar to PFIC5 patients, histologic examination of DKO livers will show ductular reaction, hepatocyte ballooning, inflammatory cell infiltration, and hepatic fibrosis. The serum profile of DKO also indicates elevation of direct bilirubin, aspartate aminotransferase (AST), and alanine aminotransferase (ALT) levels with low-to-normal GGT levels, which fully phenocopies human patients with PFIC5. Thus, DKO mice show many similarities to PFIC5 pathology.

Clinically and pathologically, PFIC5 resembles PFIC2, with severe hepatocellular injury, low-to-normal GGT, and absent BSEP expression within the first year of life ([@B4],[@B5]). However, targeted disruption of the*Abcb11*/*Bsep* gene (*Bsep*^−/−^) in a mixed genetic background mouse model results in a mild and nonprogressive cholestatic phenotype despite substantial hepatic BA accumulation. It has been suggested that this results from increased levels of nontoxic polyhydroxylated BAs and also by induction of an alternative BA export mechanism via the multidrug resistance (MDR) 1 transporter. In contrast, the*Bsep*^−/−^ allele on a pure C57BL/6 background better recapitulates human PFIC2, with increased ALT, AST, and alkaline phosphatase levels and progressive liver injury, with age-dependent hepatic fibrosis and hepatocellular damage ([@B13]).

Similar to the PFIC2 and PFIC5 pathologies, their representative animal models share many aspects of cholestatic liver injuries such as hepatomegaly and elevated hepatic BA accumulation. However, they also have distinct mechanisms beyond the overall cholestatic pathological changes. In the present study, we extensively compared the cholestatic phenotypes of DKO with those of*Bsep*^−/−^ mice, using transcriptomic and proteomic analyses to investigate their common and specific molecular pathogeneses. Finally, we identified constitutive androstane receptor (CAR) and pregnane X receptor (PXR) signaling as a hallmark of DKO-specific responses to protect the liver from further BA-induced toxicity; this response is absent in*Bsep*^−/−^. These results define the unique molecular pathogenesis of DKO as a representative PFIC5 animal model.

Materials and Methods {#s1}
=====================

Animal studies {#s2}
--------------

Male mice were used for all experiments. The C57BL/6J wild-type (WT) and C57BL/6 background*Bsep*^+/−^ mice were obtained from the Jackson Laboratory (Bar Harbor, ME; catalog nos. 000664 and 004125). Because neonates from the*Bsep*^−/−^ mother will exhibit perinatal lethality ([@B14]), male and female*Bsep*^+/−^ were mated to generate*Bsep*^−/−^ offspring.*Fxr* and*Shp* DKO (*Nr1h4*^−/−^;*Nr0b2*^−/−^),*Car* knockout (*Nr1i3*^−/−^), and*Pxr* knockout (*Nr1i2*^−/−^) mice have been previously described ([@B8],[@B15],[@B16]). Both DKO and*Fxr*:*Shp*:*Car*:*Pxr* quadruple knockout (QKO;*Nr1h4*^−/−^;*Nr0b2*^−/−^;*Nr1i3*^−/−^;*Nr1i2*^−/−^) had a lower body weight but showed normal fertility and no mortality. The institutional animal care and use committee of the Baylor College of Medicine approved all the animal studies and procedures.

Analysis of total BA level and serum biochemistry {#s3}
-------------------------------------------------

To determine the total BA levels in serum and liver tissue, the Total Bile Acid Assay kit (GWB-BQK090; GenWay Biotech, San Diego, CA) was used. Serum was separated from whole blood using a gel barrier collection tube (3T-MGA; CAPIJECT, Terumo Medical Corporation, Somerset, NJ). Liver tissue was homogenized in 70% ethanol and centrifuged for 10 minutes at 12,000 rpm to isolate clear supernatant. The 10 to 20 μL of each extract was used to determine the total BA concentration. The serum AST, ALT, and bilirubin levels were analyzed by the Center for Comparative Medicine (Baylor College of Medicine).

BA profiling using ultra-HPLC--mass spectrometry {#s4}
------------------------------------------------

For BA profiling, 20 μL of serum was mixed with 60 μL of acetonitrile (1% NH~4~OH), including lithocholic acid-D~5~ as the internal standard, and supernatant was separated by centrifugation. The liver tissue was weighed and homogenized in 6 volume of aqueous methanol (water/methanol 1:1 v/v). Next, 100 μL of each homogenate was added to 300 μL of acetonitrile (1% NH~4~OH v/v), including lithocholic acid-D~5~ as the internal standard. After centrifugation, the supernatant was transferred to a new Eppendorf vial for subsequent centrifugation. Each supernatant was transferred to a sample vial for analysis.

Next, 5 µL of the supernatant was injected into a liquid chromatography--tandem mass spectrometry (LC-MS/MS) for analysis (6490 QQQ MS; Agilent Technologies, Santa Clara, CA). BA separation was achieved using a 1260 Infinity Binary LC System (Agilent Technologies) equipped with a 100× 2.1 mm (Waters BEH C18) column. LC-MS/MS was operated in the negative mode with electrospray ionization. Mass chromatograms and spectra were acquired using MassHunter Workstation data Acquisition software (Agilent Technologies). Analysis of BAs was processed using Quantitative Analysis software (Agilent Technologies). Details are provided in the[Supplemental Experimental Procedures](#sup1){ref-type="supplementary-material"}.

Proteome profiling using LC-MS/MS {#s5}
---------------------------------

The liver tissue was homogenized by cryogenic grinding and lysed in lysis buffer (50 mM NH~5~CO~3~ and 1 mM CaCl~2~). After a quick freeze-thaw cycle twice, proteins were boiled, and freeze-thaw-denaturation procedures were repeated three times. Denatured protein was digested in trypsin twice (T9600; GenDEPOT, Katy, TX) and extracted by 50% acetonitrile/0.1% formic acid solution. The pellet was further extracted with 80% acetonitrile/0.1% formic acid, quantified (Pierce Quantitative Colorimetric Peptide Assay; Thermo Fisher Scientific, Waltham, MA), lyophilized, and fractionated, as previously described ([@B17]). Vacuum-dried peptide was dissolved in loading solution (5% methanol and 0.1% formic acid) and subjected to nano-LC-MS/MS analysis with a nano-LC1000 (Thermo Fisher Scientific) coupled to a Thermo Q-Exactive mass spectrometer (Thermo Fisher Scientific). Separated peptides were directly electro-sprayed. The instrument was operated in data-dependent mode, acquiring fragmentation spectra of the top 35 strongest ions and under direct control of Xcalibur software (Thermo Fisher Scientific).

Parent MS spectrum and higher energy collisional dissociation fragmented MS/MS spectrum were acquired in the Orbitrap Mass Analyzer (Thermo Fisher Scientific) with resolution of 140,000 and 17,500. The full MS range was 375 to 1300 m/z, and the trap target was 3,000,000 and 20,000. The obtained MS/MS spectra were searched against the target-decoy mouse refseq database in Proteome Discoverer 1.4 interface (PD1.4; Thermo Fisher Scientific) with the Mascot algorithm (Mascot 2.4; Matrix Science, Boston, MA). Area under the curve--based relative quantification was analyzed using the iBAQ algorithm and normalized to intensity-based fraction of the total to compare protein abundance ([@B17]). Details are provided in the[Supplemental Experimental Procedures](#sup1){ref-type="supplementary-material"}.

Real-time quantitative PCR {#s6}
--------------------------

Liver RNA was isolated by PureXtract RNAsol (R6101; GenDEPOT), and cDNA was synthesized using the qScript reverse transcription kit (95047; Quanta Bio, Beverly, MA). The relative expression level was determined using the quantitative PCR method and the LightCycler 480 real-time PCR system (Roche, Basel, Switzerland) with the SYBR FAST qPCR kit (KAPA Biosystems, Wilmington, MA) and calculated using the 2-^ΔΔCT^ method, normalized to the glyceraldehyde 3-phosphate dehydrogenase mRNA level. Primer information is listed in[Supplemental Table 1](#sup1){ref-type="supplementary-material"}.

Analysis of Gene Expression Omnibus data set {#s7}
--------------------------------------------

The GSE20599 (for DKO gene expression) and GSE70179 (for*Bsep*^−/−^ gene expression) data sets were analyzed using the GEO2R web-based program. To compare the data sets in two different platforms (GSE20599; Illumina mouse Ref-8, version 1.1, expression bead chip;*vs* GSE70179; Affymetrix HT MG-430 PM Array Plate), data from each platform were first sorted by official gene symbols. For duplicated gene symbols, the most significantly changed gene (*i.e.,* lower*P* value) was selected. In total, 12,959 nonduplicated genes were shared by two microarrays (78.6% of total DKO; 68.6% of total*Bsep*^−/−^). The 662 gene symbols showing a statistically significant difference (*P* \< 0.01) were collectively or separately analyzed using DAVID Bioinformatics Resources 6.8 Tools (available at:<https://david.ncifcrf.gov>; National Institute of Allergy and Infectious Diseases), and representative functional categories were displayed \[Gene Ontology--Biological Pathways (GO-BP) and Kyoto Encyclopedia of Genes and Genomes Pathway (KEGG)\] according to their expression patterns.

Immunohistochemistry {#s8}
--------------------

Immunohistochemical analysis of BSEP and CYP2B6 proteins in the mouse model and human patient liver sections was performed according to the general guidelines of immunohistochemistry. In brief, deparaffinized sections were heated in sodium citrate buffer (pH 6.0) for 15 minutes. Next, the sections were incubated with blocking buffer containing 5% normal goat serum (30 minutes), followed by diluted anti-BSEP (1:200; R31844; NSJ Bioreagents, San Diego, CA; RRID:[AB_2725751](http://antibodyregistry.org/search.php?q=AB_2725751)) and anti-CYP2B6 (1:50; NBP2-01800; Novus Biologicals, Littleton, CO; RRID:[AB_2725750](http://antibodyregistry.org/search.php?q=AB_2725750)) antibodies. After binding of biotin-conjugated secondary antibodies (rabbit: BA-1000; mouse: BA-2000; Vector Laboratories, Burlingame, CA; RRIDs:[AB_2313606](http://antibodyregistry.org/search.php?q=AB_2313606) and[AB_2313581](http://antibodyregistry.org/search.php?q=AB_2313581)), positive signal was detected using avidin-biotin complex (ABC) method using Vectastatin Elite ABC Reagent (PK-7100; Vector Laboratories) and Vector NovaRed Peroxidase Substrate Kit (SK-4800; Vector Laboratories). Next, stained sections were mounted with Poly-Mount solution (08381-940; Polysciences, Warrington, PA). A high sequence homology is present between human CYP2B6 and mouse CYP2B10 proteins (79.4%), and anti-human CYP2B6 antibody has been known to cross-react with mouse CYP2B proteins (Novus Biologicals).

Statistical analysis {#s9}
--------------------

All results are presented as the mean ± SEM, and statistical significance between WT*vs* DKO,*Bsep*^+/−^*vs Bsep*^−/−^, DKO*vs* QKO, and DKO vs*Bsep^−/−^* was calculated using the two-tailed Student*t* test with the assumption that the sample data are in a normal distribution. In a preliminary larger data-set analysis focused on*Cyp7A1* mRNA expression, we confirmed that the data followed a normal distribution and no statistically significant difference in the average value was observed between this larger data set and the smaller one (n = 3;*P* \< 0.05,*P* \< 0.01, and*P* \< 0.005). For the comparison of WT, DKO, and QKO, one-way ANOVA, followed by a*post hoc t* test with Bonferroni correction, was used. With a family of three comparisons (three groups), original significance was corrected to*P* \< 0.0167 (= 0.05/3),*P* \< 0.00333 (= 0.01/3), and*P* \< 0.00167 (= 0.005/3).

Results {#s10}
=======

DKO and Bsep^−/−^ exhibit distinct phenotype of intrahepatic cholestasis {#s11}
------------------------------------------------------------------------

As previously reported ([@B8]), combined deletion of*Fxr* and*Shp* (DKO) greatly increased the liver weight-to-body weight ratio (9%;[Fig. 1A and 1B](#F1){ref-type="fig"}). In the C57BL/6 background, introduction of the*Bsep*^−/−^ allele did not change the body weight, but the liver weight-to-body weight ratio doubled to \>9% compared with either WT or*Bsep*^+/−^ mice (5%;[Fig. 1A and 1B](#F1){ref-type="fig"}) ([@B13]). Thus, hepatomegaly occurs to a similar extent in the two cholestatic models. Hematoxylin and eosin staining of DKO liver revealed severe structural alterations with increased hepatic steatosis (arrowhead), bile duct proliferation (arrow), immune cell infiltration, polyploid nuclei, and hepatocyte ballooning ([Fig. 1C](#F1){ref-type="fig"}). The*Bsep*^−/−^ liver showed less severe phenotypes with mild bile duct proliferation (arrow) and less lipid accumulation than in the DKO liver ([Fig. 1C](#F1){ref-type="fig"}).

![DKO and*Bsep*^−/−^ mice showed hepatomegaly. (A) Representative view of whole body and liver at 3 months of age. Scale bar, 10 mm. (B) Body weight (BW), liver weight (LW), and LW/BW ratio at the time of death (n = 3 for each group). (C) Hematoxylin and eosin staining of liver (magnification, ×200). Arrowheads indicate hepatic steatosis; arrows indicate bile duct proliferation. Statistics: Student*t* test: \**P* \< 0.05 and \*\*\**P* \< 0.005 compared with each control. C, central vein; P, portal vein.](en.2018-00110f1){#F1}

Decreased BA transport due to the loss of BSEP expression causes BA accumulation in liver and blood. Hepatic BAs were highly elevated in both DKO and*Bsep*^−/−^ mice, but only DKO mice showed a robust increase of circulating BAs ([Fig. 2A](#F2){ref-type="fig"}). DKO mice harbored severe liver injury with increased serum ALT, AST (500 to 600 U/L) and conjugated hyperbilirubinemia (1 to 2 mg/dL;[Fig. 2B](#F2){ref-type="fig"}, lower-right panel). In contrast,*Bsep*^−/−^ mice showed only modest increases in these parameters ([Fig. 2B](#F2){ref-type="fig"}). Overall, despite similar extents of hepatomegaly and hepatic total BA accumulation, DKO showed more severe cholestatic liver injury than did*Bsep*^−/−^, which is generally consistent with previous reports ([@B8],[@B13]).

![Differential BA accumulation and liver injury in DKO and*Bsep*^−/−^. (A) Hepatic and serum total BA levels in DKO and*Bsep*^−/−^ serum (n = 3 for each group). (B) Serum ALT, AST, and bilirubin (direct, indirect, and total) levels. Ratio (%) indicated the proportions of direct (white) and indirect (gray) bilirubin. Statistics: Student*t* test: \**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.005 compared with each control. In some cases, the actual*P* value is presented. TBA, total bile acid.](en.2018-00110f2){#F2}

DKO preferentially enriches cholic acid--derived BAs {#s12}
----------------------------------------------------

The primary BAs, cholic acid (CA) and chenodeoxycholic acid (CDCA), are further modified into CA-derived BAs (*i.e.,* glyco-CA, tauro-CA) or CDCA-derived BAs \[*i.e.,* tauro-CDCA,*α*/*β*--muricholic acid (MCA), tauro-*α*/*β*MCA\] in liver ([@B18]). Metabolomic analysis revealed that DKO liver preferentially contains CA-derived BAs (CA, glyco-CA, and tauro-CA), and*Bsep*^−/−^ liver accumulated CDCA-derived BAs (tauro-CDCA,*α*/*β*MCA, and tauro-*α*/*β*MCA;[Fig. 3A](#F3){ref-type="fig"};[Supplemental Fig. 1A](#sup1){ref-type="supplementary-material"}). Similarly, although both types of BAs were mostly elevated ([Supplemental Fig. 1B](#sup1){ref-type="supplementary-material"}), CA-derived BAs were more proportionally increased in DKO serum, and CDCA-derived BAs were elevated in*Bsep*^−/−^ serum ([Fig. 3B](#F3){ref-type="fig"}). Overall, these results strongly suggest differential regulation of BA synthetic pathways in DKO and*Bsep*^−/−^ livers.

![The DKO and*Bsep*^−/−^ mice showed differential BA profiling. BA composition of (A) liver and (B) serum in WT, DKO, and*Bsep*^−/−^ mice. BAs were quantified as the percentage of total BA analyzed (100%). CA-derived primary BAs shown in blue and dark blue \[CA, tauro-CA (TCA), glyco-CA (GCA), deoxycholic acid (DCA), and tauro-DCA (TDCA)\]. CDCA-derived primary BAs shown in orange or dark red \[CDCA, tauro-CDCA (TCDCA),*αβ*MCA, and tauro-*αβ*MCA (T*αβ*MCA)\]. TUDCA, tauro-ursodeoxycholic acid.](en.2018-00110f3){#F3}

Primary BAs are converted into secondary BAs by intestinal bacteria, and then some are absorbed and returned to the liver via enterohepatic circulation. Although a few secondary BAs were detectible in our assay, they were highly increased in DKO serum but not in liver ([Supplemental Fig. 1C](#sup1){ref-type="supplementary-material"}), indicating that hepatic BA uptake might be blunted in the DKO liver. Circulating levels of secondary BAs were not increased in*Bsep*^−/−^ serum ([Supplemental Fig. 1C](#sup1){ref-type="supplementary-material"}).

Transcriptomic and proteomic profiling of BA-metabolizing genes {#s13}
---------------------------------------------------------------

To decipher the molecular basis of differential pathogenesis in DKO and*Bsep*^−/−^ livers, we explored hepatic mRNA and protein expression of a panel of genes involved in BA synthesis, metabolism, and transport ([Supplemental Tables 2 and 3](#sup1){ref-type="supplementary-material"}). In the DKO liver, mRNA and protein levels of classic*de novo* BA synthetic enzymes were dramatically induced (CYP7A1 and CYP8B1), and the major canalicular BA transporter BSEP was significantly reduced ([Fig. 4A and 4B](#F4){ref-type="fig"}, upper), explaining the abnormal hepatic BA accumulation in DKO ([Fig. 2A](#F2){ref-type="fig"}). Although the mRNA levels were increased ([Fig. 4A and 4B](#F4){ref-type="fig"}, upper), the protein levels of alternative canalicular BA transporters (ABCB1A and ABCC2) were unchanged, but ABCC3 (MRP3), a basolateral BA transporter, was increased, enabling export of excess BA into the circulation ([Fig. 2A](#F2){ref-type="fig"}) and eventual elimination of toxic BA via the urine. BA influx is mediated by sodium/BA cotransporter (SLC10A1, NTCP), which can be decreased in cholestatic liver injury in response to FXR/SHP independent pathways ([@B19]). SLC10A1 expression showed a tendency toward a decrease ([Fig. 4A](#F4){ref-type="fig"} and[Fig. 5A](#F5){ref-type="fig"}, upper), potentially restraining excessive uptake of secondary BAs in the DKO liver ([Supplemental Fig. 1C](#sup1){ref-type="supplementary-material"}).

![Expression profile of representative genes involved in BA homeostasis. The (A) mRNA and (B) protein profile of representative BA synthesis, metabolism, transport, and uptake genes in 3-month-old DKO (upper) and*Bsep*^−/−^ (lower) mice was analyzed using real-time quantitative PCR and proteomics. Relative protein levels are indicated as intensity-based fraction of the total (iFOT). In addition to the official gene symbol, the common gene name is given in parentheses, if necessary. Statistics: Student*t* test: \**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.005 compared with each control. In some cases, the actual*P* value is presented. ND, not detected.](en.2018-00110f4){#F4}

![Specific activation of CYP2B and CYP2C in DKO. (A) Upregulated genes of CYP and GST (GS transferase) gene family (*P* \< 0.005 and*P* \< 0.001 in DKO, respectively).*P* values in DKO separately indicated by asterisks (\*, \*\*, \*\*\*). Representative CYP and GST gene expression in (B) DKO and (C)*Bsep*^−/−^ were confirmed by real-time quantitative PCR. Statistics: Student*t* test: \**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.005 compared with each control. In some cases, the actual*P* value is presented.](en.2018-00110f5){#F5}

The*Bsep*^−/−^ liver showed quite distinct mRNA and protein profiles compared with the DKO liver. Despite unchanged mRNA levels, CYP7A1 protein was significantly increased but to a lesser extent than in DKO liver ([Fig. 4A and 4B](#F4){ref-type="fig"}, lower). CYP8B1 expression, which mediates conversion of 7*α*-hydroxycholesterol to CA, was totally abolished, favoring CDCA production over CA synthesis ([Fig. 3A](#F3){ref-type="fig"} and[Fig. 4A and 4B](#F4){ref-type="fig"}, lower) ([@B20]). For the BA metabolism genes, CYP3A11 was significantly induced but other enzymes such as CYP2B10, UGT1A1, and SULT2A1 were unchanged ([Fig. 4A and 4B](#F4){ref-type="fig"}, lower;[Supplemental Tables 3 and 4](#sup1){ref-type="supplementary-material"}). CYP3A11 upregulation is thought to be responsible for the polyhydroxylation of BAs in*Bsep*^−/−^ ([@B21]). The BSEP level was strongly diminished, but other BA transporters (ABCB1A and ABCC2) were highly induced, compensating for blunted BSEP function through alternative canalicular export of conjugated BAs. In contrast to DKO, basolateral BA transporter proteins were unchanged in*Bsep*^−/−^ (ABCC3 and ABCC4;[Fig. 4A and 4B](#F4){ref-type="fig"}, lower), restraining BA efflux into the blood circulation ([Fig. 2A](#F2){ref-type="fig"}). Overall, these results collectively identify underlying molecular mechanisms for the distinct BA phenotypes of DKO and*Bsep*^−/−^ mice ([Figs. 1](#F1){ref-type="fig"} and[2](#F2){ref-type="fig"}).

DKO specifically activates CYP gene family {#s14}
------------------------------------------

To further define the specific molecular responses in two different models, we compared available DKO and*Bsep*^−/−^ microarrays (GSE20599 and GSE70179). Among 12,959 common gene symbols, DKO and*Bsep*^−/−^ microarrays identified 2210 (17.1% of total) and 2069 (16.0% of total) of differentially regulated genes (*P* \< 0.01), respectively. The GO-BP and KEGG analyses using DAVID tools indicated overlapping and nonoverlapping groups in DKO and*Bsep*^−/−^ microarrays ([Supplemental Fig. 2B](#sup1){ref-type="supplementary-material"};[Supplemental Tables 4 and 5](#sup1){ref-type="supplementary-material"}).

A total of 662 genes were altered in both microarrays, and they overlapped very significantly (hypergeometric test,*P* = 7.41\*10^−76^;[Supplemental Fig. 2A and 2C](#sup1){ref-type="supplementary-material"}). GO-BP and KEGG analysis of the 252 increased genes identified groups of genes in chemical carcinogenesis \[glutathione*S*-transferases (GSTs):*Gsta2*,*Gstm1*,*etc.*\], immune responses (*Cd14*,*Tlr2*,*Cxcl10*,*Il17*,*etc.*), and cellular proliferation (*Jun*,*Jund*,*etc.*), which correlates with liver injury and hepatomegaly phenotype. In contrast, genes in the peroxisome and PPAR signaling pathway were largely downregulated (*Ppara*,*Acox1*,*Acsl1*,*etc.*). Interestingly, 256 genes regulated in the opposite manner (increased in DKO and decreased in*Bsep*^−/−^) were also grouped into chemical carcinogenesis according to the CYP gene responses (*i.e.,Cyp2b9*,*Cyp2b10*,*Cyp2b13*;[Supplemental Fig. 2D](#sup1){ref-type="supplementary-material"}).

The CYP genes and GSTs are responsible for clearance of xenobiotics and toxic cellular components such as BA and bilirubin. Many CYP genes and GSTs were highly increased in DKO ([Fig. 5A](#F5){ref-type="fig"}). In contrast,*Bsep*^−/−^ had only increased GSTs and showed a mixed pattern of CYP genes ([Fig. 5A](#F5){ref-type="fig"};[Supplemental Fig. 3A and 3B](#sup1){ref-type="supplementary-material"}). In particular, both*Cyp2b* and*Cyp2c* genes were clearly induced in DKO ([Fig. 5B](#F5){ref-type="fig"}) but were completely blunted in*Bsep*^−/−^ ([Fig. 5C](#F5){ref-type="fig"}). The protein levels showed similar patterns ([Supplemental Fig. 4A and 4B](#sup1){ref-type="supplementary-material"}). Expression of GSTs and glutathione peroxidases was commonly upregulated in both DKO and*Bsep*^−/−^ livers ([Fig. 5B and 5C](#F5){ref-type="fig"}, right). These results strongly indicate differential transcriptional control accounting for DKO-specific induction of CYP genes.

Activated CAR/PXR increases CYP gene transcription to improve DKO cholestasis {#s15}
-----------------------------------------------------------------------------

Expression of CYP genes is regulated by multiple transcription factors, including, not only the xenobiotic receptors CAR and PXR, but also PPAR*α*, aryl hydrocarbon receptor (AHR), and nuclear transcription factor E2-related factor 2 (NRF2) ([@B22]). In addition to a variety of exogenous activators, the two xenobiotic nuclear receptors are known to be activated by a variety of endogenous ligands and stress signals, including hydrophobic BAs and bilirubin ([@B23]). Initial studies with*Fxr*:*Shp*:*Car* and*Fxr*:*Shp*:*Pxr* triple mutant mice did not show a major impact on P450 gene responses, suggesting functional redundancy. Thus, to genetically test the transcriptional function of CAR and PXR in the DKO liver, we generated*Fxr*:*Shp*:*Car*:*Pxr* QKO mice ([Supplemental Fig. 5](#sup1){ref-type="supplementary-material"}). The strong DKO induction of*Cyp2b* and*Cyp2c* was totally blunted in QKO livers ([Fig. 6A](#F6){ref-type="fig"}). In contrast, the GST genes, which are also upregulated in*Bsep*^−/−^ livers ([Fig. 1C](#F1){ref-type="fig"}), were partly decreased or unaffected ([Fig. 6B](#F6){ref-type="fig"}). These results are consistent with the well-recognized regulation of*Cyp2b* and*Cyp2c* genes by CAR and PXR ([@B24],[@B25]).

![Deletion of CAR/PXR exacerbates BA-induced hepatotoxicity. The mRNA expression of representative (A) CYP and (B) GSTs was evaluated by real-time quantitative PCR (n = 3 for each group). (C) Serum bilirubin levels in DKO and QKO. Ratio (%) indicated the proportions of direct (white) or indirect (gray) bilirubin compared with total bilirubin. (D) Hematoxylin and eosin images of WT, DKO, and QKO liver. Black arrowheads indicate hepatic steatosis; white arrowheads indicate cytoplasmic clearing and severe hepatocyte swelling. Statistics: (A and B)*P* values of one-way ANOVA test indicated.*Post hoc t* test with Bonferroni correction:^†,\#^*P* \< 0.0167,^††,\#\#^*P* \< 0.00333,^†††,\#\#\#^*P* \< 0.00167;^†^compared with WT;^\#^compared with DKO. (D) Student*t* test: \**P* \< 0.05, \*\*\**P* \< 0.005 compared with DKO.](en.2018-00110f6){#F6}

Both CAR and PXR have been strongly linked to BA detoxification in response to cholestatic liver injury ([@B26],[@B27]). However, both the somewhat unexpected viability of the QKO mice and their retention of the GST gene responses raised the question of whether CAR and PXR activation in the DKO livers is protective. Consistent with the predicted beneficial effect, loss of CAR/PXR in the cholestatic DKO liver not only affected*Cyp2b/2c* gene transcription but also exacerbated BA-induced liver injury. The QKO mice experienced substantial growth retardation, in particular from 3 to 6 months of age, and an increase in external signs of poor health relative to the DKO mice. Although the serum AST and ALT levels did not differ from those of the DKO mice (data not shown), the total serum bilirubin levels were strongly upregulated (sevenfold) in QKO relative to DKO. This was stronger for unconjugated indirect bilirubin (32-fold) compared with glucuronidated direct bilirubin (4-fold;[Fig. 6C](#F6){ref-type="fig"}). Histological analysis also showed accelerated liver injury in QKO, as indicated by more severe cytoplasmic clearing, giant cell transformation, and hepatocyte swelling ([Fig. 6D](#F6){ref-type="fig"}, white arrowhead). These results suggest that activation of CAR/PXR signaling in DKO protects against the liver injury due to excess bilirubin accumulation and defective bilirubin conjugation.

Upregulated CYP2B protein expression in DKO and PFIC5 liver {#s16}
-----------------------------------------------------------

To directly analyze the induction of CYP2B expression in the DKO liver, we stained liver sections with CYP2B-specific antibody. As expected, canalicular BSEP expression was specifically detectible in WT and*Bsep*^+/−^ livers, which was markedly reduced in DKO and QKO and, as expected, totally absent in*Bsep*^−/−^ ([Fig. 7A](#F7){ref-type="fig"}, arrowhead in upper panel). Basal CYP2B expression was weakly present around the central veins in the WT and was highly increased in the DKO liver. This induction was mostly blunted by CAR/PXR deletion (QKO). As expected from the mRNA and protein expression ([Fig. 4](#F4){ref-type="fig"}), no change was found in CYP2B protein expression in the*Bsep*^−/−^ liver ([Fig. 7A](#F7){ref-type="fig"}, lower panel).

![Upregulation of CYP2B expression in DKO and PFIC5 livers. (A) Mouse liver sections from WT, DKO, QKO,*Bsep*^+/−^, and*Bsep*^−/−^ mice were stained with anti-BSEP (upper panel) and anti-CYP2B6 (lower panel) antibodies. Next, nuclei were counterstained with hematoxylin. Arrowheads indicate canalicular BSEP expression. (B) Cirrhotic liver sections from end-stage disease of patients with PFIC5 and PFIC2 were stained with anti-CYP2B6 antibody. (Inset) Parenchymal CYP2B6 staining. Arrowhead indicates positive CYP2B6 staining in a biliary tract.](en.2018-00110f7){#F7}

We then examined whether differential CYP2B regulation is conserved in human PFIC5 and PFIC2 livers. We analyzed CYP2B6 expression in liver sections from patients with previously diagnosed PFIC5 and PFIC2 showing end-stage liver cirrhosis. CYP2B6 expression was detected in PFIC5 hepatocytes, but PFIC2 did not have CYP2B6-positive hepatocytes ([Fig. 7B](#F7){ref-type="fig"}, inset). Biliary epithelial cells generally expressed high levels of CYP2B6 proteins regardless of the diagnosis ([Fig. 7B](#F7){ref-type="fig"}, arrowhead), consistent with the previous observation in a normal donor \[Protein Atlas database ([@B28]);[Supplemental Fig. 6](#sup1){ref-type="supplementary-material"}\]. These human data strongly support our findings of activated CAR/PXR-CYP2B signaling in DKO mice but not in*Bsep*^−/−^ mice.

Discussion {#s17}
==========

The DKO and*Bsep*^−/−^ models of cholestasis showed similar primary responses, in particular, comparable levels of hepatomegaly and total BA elevations. However, both the molecular mechanisms that account for the increased BA levels and the secondary consequences of these elevations are quite different.

Loss of the FXR/SHP axis in DKO livers dramatically stimulates BA synthesis via strong induction of CYP7A1 and CYP8B1 and inhibits canalicular BA transport via suppression of ABCB11/BSEP, leading to BA overload ([Supplemental Fig. 7](#sup1){ref-type="supplementary-material"}). Elevated hepatic BAs are forced into the circulation by increased ABCC3/MRP3 expression ([Fig. 4](#F4){ref-type="fig"}), resulting in dramatic elevation of serum BA levels ([Fig. 2A](#F2){ref-type="fig"};[Supplemental Fig. 1B](#sup1){ref-type="supplementary-material"}). The increased BA pool activates CAR/PXR signaling to enhance BA and bilirubin metabolism and conjugation through the induction of CYP and GST genes. Although the initial results indicated that the P450 and GST responses were not ablated in either the*Fxr*:*Shp*:*Car* or the*Fxr*:*Shp*:*Pxr* triple knockout models, the functional role of the CAR/PXR pathway was strongly confirmed by the observation that deletion of both (QKO) completely abolished*Cyp2b* and*Cyp2c* induction ([Fig. 6A](#F6){ref-type="fig"}). This suggests that both CAR and PXR contribute to*Cyp2b* and*Cyp2c* transactivation, which is consistent with numerous previous studies ([@B24],[@B25]). The more severe phenotype of the QKO relative to the DKO confirmed the expected protective effects of the CAR/PXR axis, especially in the context of bilirubin clearance. However, both the somewhat unexpected viability of the QKO mice and their continued induction of GST enzymes suggest that important protective pathways are active in the QKO liver and, likely, also in the DKO liver. The specific targets and functions of CAR and PXR in DKO pathogenesis and the identity of such additional pathways need further investigation.

In contrast to DKO, the*Bsep*^−/−^ livers highly induced alternative canalicular BA transporters (MDR1 and MRP2) without changes in basolateral transporter expression (MRP3 and MRP4), relieving excess hepatic BA overload through the biliary system ([Fig. 2A](#F2){ref-type="fig"} and[Fig. 4](#F4){ref-type="fig"};[Supplemental Fig. 7](#sup1){ref-type="supplementary-material"}). This alternative pathway preferentially exports hydroxylated and, subsequently, conjugated BAs into the bile duct, which partially rescues the total BA output in*Bsep*^−/−^ ([@B29]). Instead of CAR/PXR activation as in DKO, FXR is likely activated in*Bsep*^−/−^ livers by the increased BA levels. In accord with this, representative positive target genes of FXR are highly upregulated in*Bsep*^−/−^ but are mostly blunted or slightly increased in DKO ([Supplemental Fig. 8](#sup1){ref-type="supplementary-material"}). FXR activation is likely also responsible for the opposite regulation of its negative target*Cyp8b1* ([@B30]), which was strongly decreased in*Bsep*^−/−^ but was increased in both*Fxr* single knockout and DKO ([Fig. 4A](#F4){ref-type="fig"} and GSE20599 data set; data not shown). Additional*Bsep*^−/−^-specific genes such as*Abcb1a* (MDR1A),*Slc51b* (OST*β*),*Abcb4* (MDR2), and GSTs are*bona fide* FXR targets ([Fig. 4](#F4){ref-type="fig"}) that regulate BA homeostasis ([@B31]). Therefore, despite an intrahepatic cholestasis phenotype that initially appeared similar in DKO and*Bsep*^−/−^ livers, it is apparent that the specific molecular defects in BA homeostasis are quite different. This might be crucial to understanding the pathology of intrahepatic cholestasis in animal models and in human patients.

Our results suggest several functionally interrelated mechanisms that might contribute to the differential pathology. The first is the substantial difference in the composition of the BA pools, because FXR activation in*Bsep*^−/−^ livers nearly eliminates the 12-*α*-hydroxylation function of CYP8B1. This could be expected to make the BA pool more hydrophobic and toxic; however, it has previously been suggested that substantial secondary hydroxylation of this*Bsep*^−/−^ BA pool via CYP3A11 decreases toxicity ([@B21]). This secondary effect is definitely consistent with the more benign*Bsep*^−/−^ phenotype but raises two important questions that do not yet have clear answers. The first question is because the CAR/PXR axis is apparently not activated in the*Bsep*^−/−^ livers ([Fig. 4](#F4){ref-type="fig"}), what is the protective pathway or pathways that differentially induce CYP3A11 and GSTs? Candidates include the other transcription factors AHR and NRF2 ([@B35]), because recent evidence has suggested that crosstalk between the AHR and NRF2 pathways might protect cells from oxidative stress and cholestatic liver injury ([@B39]). The second question is why is the even larger induction of*Cyp3a11* and other CYP in DKO livers relative to*Bsep*^−/−^ livers associated with a worse, rather than a better, outcome?

One simple interpretation is that the differential DKO and*Bsep*^−/−^ phenotypes are simply secondary to some other aspect of the BA pool. In this scenario, the somehow more benign*Bsep*^−/−^ BA pool would result in milder cholestasis, less liver injury, and no CAR/PXR activation ([@B13],[@B21],[@B42]). However, previous observations with young*Fxr* single knockout mice (3 weeks old) showed substantial CYP gene induction in circumstances that are largely free of cholestatic liver injury ([@B8]) (GSE20599 data set; data not shown), suggesting that that loss of FXR is sufficient to primarily activate CAR/PXR. Previous results also showed that CAR and PXR can be activated by dietary CA, regardless of the*Fxr* genotype ([@B43]). CAR and PXR are indirectly and directly activated by bilirubin and certain hydrophobic BAs to control BA/bilirubin detoxification and clearance processes ([@B44]). Thus, loss of FXR/SHP might preferentially activate CAR/PXR axis through CA-derived BAs and/or bilirubin. In contrast, the*Bsep*^−/−^ livers showed much more modest changes in CA-derived BAs, instead favoring CDCA synthesis to activate FXR ([Fig. 3A](#F3){ref-type="fig"}). Also, FXR can reportedly inhibit CAR/PXR activation in certain gene promoters ([@B49]). These results indicate that loss of FXR might be a specific requirement for direct and indirect CAR/PXR activation.

In accordance with this, we found that activation of CAR/PXR signaling is unique for DKO and PFIC5 compared with other cholestasis models, in addition to*Bsep*^−/−^. Bile duct-ligated mice, a model of extrahepatic cholestasis, do not show*Cyp2b* and*Cyp2c* induction ([@B21]) ([Supplemental Fig. 9A](#sup1){ref-type="supplementary-material"}). In human patients with biliary atresia, the most detrimental type of pediatric cholestasis,*CYP2B* and*CYP2C* genes are mostly decreased or unchanged ([Supplemental Fig. 9B](#sup1){ref-type="supplementary-material"}). Thus, activation of the CAR/PXR-CYP2B/2C axis is specific for PFIC5 and DKO pathogenesis ([Fig. 7B](#F7){ref-type="fig"}).

FXR activation can clearly improve cholestatic liver injury by direct and indirect inhibition of BA synthesis ([@B1]). Thus, treatment with the FXR agonist GW4064, an FXR, protects against*α*-naphthylisothiocyanate-- or bile duct ligation--induced hepatotoxicity in animal models ([@B30]). However, decreased FXR activity has also been associated with beneficial effects in the bile duct ligation model by induction of BA conjugation and clearance processes ([@B50],[@B51]). The induction of protective CAR/PXR signaling on loss of FXR function might explain this apparent paradox.

In conclusion, collectively, we found that animal models of intrahepatic cholestasis can have very distinct molecular pathogenesis. Although they have overlapping phenotypes and gene expression, the CAR/PXR pathway is differentially activated in DKO, and likely PFIC5, livers to enhance BA and bilirubin detoxification processes. In contrast, in*Bsep*^−/−^ livers, intact FXR signaling has the expected protective effects. These distinct molecular phenotypes might provide insights to understand the unique pathogenesis of the distinct human PFIC syndromes, which might require very different treatment modalities.
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ABC

:   avidin-biotin complex

AHR

:   aryl hydrocarbon receptor

ALT

:   alanine aminotransferase

AST

:   aspartate aminotransferase

BA

:   bile acid

BSEP

:   bile salt export pump

CA

:   cholic acid

CAR

:   constitutive androstane receptor

CDCA

:   chenodeoxycholic acid

CYP

:   cytochrome P450

DKO

:   *Fxr* and*Shp* double knockout

FXR

:   farnesoid X receptor

GGT

:   *γ*-glutamyl transferase

GO-BP

:   Gene Ontology-Biological Pathways

GST

:   glutathione*S*-transferase

KEGG

:   Kyoto Encyclopedia of Genes and Genomes Pathway

LC-MS/MS

:   liquid chromatography--tandem mass spectrometry

MCA

:   muricholic acid

MDR

:   multidrug resistance

NRF2

:   nuclear transcription factor E2-related factor 2

PFIC

:   progressive familial intrahepatic cholestasis

PPAR

:   peroxisome proliferator--activated receptor

PXR

:   pregnane X receptor

QKO

:   *Fxr:Shp:Car:Pxr* quadruple knockout

SHP

:   small heterodimer partner

WT

:   wild-type
